Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.rdc.2014.12.005 http://scihub22266oqcxt.onion/10.1016/j.rdc.2014.12.005 C4385198!4385198!25836640     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25836640.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Rheum+Dis+Clin+North+Am 2015 ; 41 (2): 237-48 Nephropedia Template TP {{tp|p=25836640|t=2015. Interstitial Lung Disease in Scleroderma |pdf=|usr=}}{{25836640}} gab.com Text Interstitial Lung Disease in Scleroderma JO: Rheum Dis Clin North Am http://www.kidney.de/pget.php?&tw=1&pmid=25836640 #FOAvip Systemic sclerosis (SSc) is a heterogeneous disease of unknown etiology and with limited effective therapies. It is characterized by autoimmunity, vasculopathy and fibrosis and is clinically manifested by multi-organ involvement. Interstitial lung disease (ILD) is a common complication of the disease and is associated with significant morbidity and mortality. The diagnosis of ILD hinges upon careful clinical evaluation as well as pulmonary function tests (PFTs) and high resolution computed tomography (HRCT). A number of pro-inflammatory and pro-fibrotic mediators are involved in the pathogenesis of SSc-ILD, with transforming growth factor-beta (TGF-?) playing a key role in the development of fibrosis. Despite recent advances in the understanding of the mechanisms of disease initiation and progression, effective therapeutic options are still limited. A number of experimental therapies are currently in early phase clinical trials and show promise. Twit Text FOAVip Interstitial Lung Disease in Scleroderma ????Rheum Dis Clin North Am http://www.kidney.de/pget.php?&tw=1&pmid=25836640 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25836640 #FOAvip English Wikipedia <ref>{{Cite pmid|25836640}}</ref> Interstitial Lung Disease in Scleroderma #MMPMID25836640 Schoenfeld SR; Castelino FV Rheum Dis Clin North Am 2015[May]; 41 (2): 237-48 PMID25836640show ga Systemic sclerosis (SSc) is a heterogeneous disease of unknown etiology and with limited effective therapies. It is characterized by autoimmunity, vasculopathy and fibrosis and is clinically manifested by multi-organ involvement. Interstitial lung disease (ILD) is a common complication of the disease and is associated with significant morbidity and mortality. The diagnosis of ILD hinges upon careful clinical evaluation as well as pulmonary function tests (PFTs) and high resolution computed tomography (HRCT). A number of pro-inflammatory and pro-fibrotic mediators are involved in the pathogenesis of SSc-ILD, with transforming growth factor-beta (TGF-?) playing a key role in the development of fibrosis. Despite recent advances in the understanding of the mechanisms of disease initiation and progression, effective therapeutic options are still limited. A number of experimental therapies are currently in early phase clinical trials and show promise. äInterstitial Lung Disease in Scleroderma (epmc).pdf DeepDyve Pubget Overpricing